 | • レポートコード：MRC-IM30230 • 出版社/出版日：IMARC / 2022年11月 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2021年に16.8億ドルであった世界の卵巣がん市場規模が、2022年から2027年の間にCAGR 11.40％で成長し、2027年までに33.4億ドルに達すると予測しています。本調査レポートでは、卵巣がんの世界市場について総合的に調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、種類別（上皮性卵巣がん、胚細胞卵巣がん、間質細胞卵巣がん）分析、治療法別（免疫療法、化学療法、標的療法、手術、その他）分析、エンドユーザー別（病院、在宅医療、専門センター、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目をまとめています。なお、本書に掲載されている企業情報には、AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd.などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の卵巣がん市場規模：種類別 - 上皮性卵巣がんの市場規模 - 胚細胞卵巣がんの市場規模 - 間質細胞卵巣がんの市場規模 ・世界の卵巣がん市場規模：治療法別 - 免疫療法の市場規模 - 化学療法の市場規模 - 標的療法の市場規模 - 手術の市場規模 - その他治療法の市場規模 ・世界の卵巣がん市場規模：エンドユーザー別 - 病院における市場規模 - 在宅医療における市場規模 - 専門センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の卵巣がん市場規模：地域別 - 北米の卵巣がん市場規模 - アジアの卵巣がん市場規模 - 欧州の卵巣がん市場規模 - 中南米の卵巣がん市場規模 - 中東・アフリカの卵巣がん市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global ovarian cancer market size reached US$ 1.68 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 3.34 Billion by 2027, exhibiting a growth rate (CAGR) of 11.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Ovarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals’ general health, and the size and type of ovarian cancer.
Ovarian Cancer Market Trends:
The increasing prevalence of epithelial, stromal, and germ cell ovarian cancer, especially amongst the female geriatric population, due to the genetic mutation of breast cancer gene 1 (BRCA1) or BRCA2, is primarily driving the market growth. In line with this, the rising need for effective therapeutic drugs, such as bevacizumab (Avastin) and pazopanib (Votrient), is acting as another growth-inducing factor. Additionally, the widespread adoption of combination therapies in the healthcare sector to prevent drug resistance and increase treatment efficacy is supporting the market growth. Moreover, the ongoing patent expiration of branded medications has prompted governments and pharmaceutical companies to launch novel recombinant drugs, which, in turn, is propelling market growth. Furthermore, extensive initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers regarding the symptoms, treatments, and benefits of early ovarian cancer diagnosis are impelling the market growth. Apart from this, strategic collaborations amongst key players and continuous research and development (R&D) activities to produce efficient therapeutic interventions are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ovarian cancer market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment type and end user.
Breakup by Type:
Epithelial Ovarian Cancer
Germ Cell Ovarian Cancer
Stromal Cell Ovarian Cancer
Breakup by Treatment Type:
Immunotherapy
Chemotherapy
Targeted Therapy
Surgery
Others
Breakup by End User:
Hospitals
Homecare
Speciality Centre
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global ovarian cancer market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ovarian cancer market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global ovarian cancer market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Ovarian Cancer Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Epithelial Ovarian Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Germ Cell Ovarian Cancer
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Stromal Cell Ovarian Cancer
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Treatment Type
7.1 Immunotherapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Chemotherapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Targeted Therapy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Surgery
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Homecare
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Speciality Centre
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Amneal Pharmaceuticals Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.3 AstraZeneca plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eli Lilly and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 F. Hoffmann-La Roche AG
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 GSK plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Hikma Pharmaceuticals PLC
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Lupin Limited
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Pfizer Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2021
Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2021
Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2021
Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2021
Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2021
Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis